An interventional study of Sample collection in IBS (Irritable Bowel Syndrome), sponsored by Guy Boeckxstaens. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Guy Boeckxstaens · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Irritable Bowel Syndrome with a site in Belgium — 12 open to participants now, 13 under way, 3 of them phase 3. Irritable Bowel Syndrome · Belgium.
Among the 32 studies in Irritable Bowel Syndrome with a site in Belgium, this one is the 20th largest by planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2026, is one of 16 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 32nd registered.
1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.
Browse Irritable Bowel Syndrome studies →12 of the 32 studies in Irritable Bowel Syndrome with a site in Belgium are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Belgium, United States, Canada and 7 more countries
Ages 18–75
Eli Lilly and Company · Sites in Belgium, United States, Canada and 5 more countries
Ages 18–75
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
Devintec Sagl · Sites in Belgium, France, Italy and 1 more country
Ages 18–65
Biokuris s.a. · Sites in Belgium, France
Ages 18–75
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 900 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 90 across the 29 interventional studies, 355 across the 3 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
Guy Boeckxstaens is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Guy Boeckxstaens has 2 studies filed under Irritable Bowel Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Irritable Bowel Syndrome with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05815602Phase 3Guy BoeckxstaensEbastine Versus Mebeverine in IBS Patients | 2027-10-01 |
| NCT07176078Universitair Ziekenhuis BrusselEvaluating the Added Benefit of Osteopathic Care to a Flexi-FODMAP Diet in Fibromyalgia Patients With Irritable Bowel Syndrome | 2026-12 |
| NCT07545772Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) | 2027-07 |
| NCT06681012Devintec SaglGelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome | 2027-07 |
| NCT07545759Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Irritable Bowel Syndrome with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study evaluating the effect of UCB8600 on mast cell activation in the human gut:
IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success.
Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms. More specifically, they set histamine free when activated which heightens nerve sensitivity in the intestines which probably contributes to the abdominal pain. A new product called "UCB8600" is hypothesized to be able to counteract this by causing less mast cells to be activated. In this study we'll test this by administering UCB8600 on intestinal tissue and see if there is less mast cell activation. If the study produces good results, this new product could potentially be used as a treatment for IBS in the future.
Inclusion Criteria group 1 (resection tissue from surgery patients = healthy volunteers):
Exclusion Criteria group 1 (resection tissue from surgery patients = healthy volunteers):
Inclusion Criteria group 2 (rectal from IBS patients):
Exclusion Criteria group 2 (rectal biopsies from IBS patients):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Collection of colonic resection material of subjects undergoing abdominal surgery due to malignancies
Other: Sample collection
Collection of rectal biopsies of IBS patients
Other: Sample collection
Collection of colonic resection material (surgery patients) and rectal biopsies (IBS patients)
Total percentage of degranulated mast cells, detected using fluorescence microscopy
Using an avidin essay and fluorescence microscopy, the percentage of degranulated mast cells will be quantified
Time frame: After finishing the essay, approximately on day 2
Total corrected cellular fluorescence (TCCF) per mast cell
Using an avidin essay and fluorescence microscopy, the TCCF per mast cell will be quantified
Time frame: After finishing the essay, approximately on day 2
Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.
Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 14 months is below that.
Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guy Boeckxstaens